Rituximab [rituximab]
- Terms
-
Mabthera
-
CD20 Antibody, Rituximab
GP2013
IDEC-C2B8
IDEC-C2B8 Antibody
Mabthera
Rituxan
A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.
- DUI
- D000069283 MeSH Browser
- CUI
- M0244307
- History note
- 2016 (1995)
- Public note
- 2016; RITUXIMAB was indexed under ANTIBODIES, MONOCLONAL, MURINE-DERIVED 1995-2016
Allowable subheadings
- AD
- administration & dosage 146
- AE
- adverse effects 64
- AN
- analysis
- BI
- biosynthesis
- BL
- blood
- CF
- cerebrospinal fluid
- CH
- chemistry 1
- CL
- classification 1
- DE
- drug effects 3
- EC
- economics 4
- GE
- genetics
- HI
- history
- IM
- immunology 2
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics 12
- PD
- pharmacology 81
- PH
- physiology
- PO
- poisoning
- RE
- radiation effects
- TU
- therapeutic use 311
- TO
- toxicity
- UL
- ultrastructure
- UR
- urine
131I-rituximab Chemical MeSH Browser
177Lu-DOTA-rituximab Chemical MeSH Browser
89Zr-rituximab Chemical MeSH Browser
R-CVP protocol Chemical MeSH Browser
R-FCM protocol Protocol MeSH Browser
rituximab-alliinase conjugate Chemical MeSH Browser
technetium 99m carbonyl DTPA-rituximab Chemical MeSH Browser
technetium 99m rituximab Chemical MeSH Browser
terbium-rituximab Chemical MeSH Browser
thorium-227-DOTA-rituximab Chemical MeSH Browser
thorium-4-benzyl-DOTA-rituximab Chemical MeSH Browser